CD47 and primitive neuroectodermal tumor: A blockade of the CD47–SIRPα interaction using humanized antibodies to CD47 (Hu5F9-G4) has yielded promising results in a number of human malignancies, including pediatric brain tumors: medulloblastoma, atypical teratoid rhabdoid tumors, primitive neuroectodermal tumor, pediatric glioblastoma, and diffuse intrinsic pontine glioma [93].